A new study reports that a simple blood test score—combining hemoglobin with the albumin-to-alkaline phosphatase ratio—can predict which advanced lung cancer patients benefit from immunotherapy (ID: fe41d09a1b6c0e65). The approach aims to add practical patient stratification beyond tumor tissue-based biomarkers. The findings position routine laboratory parameters as potential decision aids for treatment selection, with the study suggesting survival differences tied to the index across immunotherapy-treated cohorts.